5/26/2016

Acamprosate Calcium Tablets

Reason for the Shortage

- Glenmark Pharmaceuticals could not provide a reason for the shortage.
- Mylan could not provide a reason for the shortage.
- Actavis discontinued Campral tablets in 2014.

Available Products

- Acamprosate calcium oral tablet, Glenmark, 333 mg, bottle, 180 count, NDC 68462-0435-18
- Acamprosate calcium oral tablet, Mylan, 333 mg, bottle, 180 count, NDC 00378-6333-80
- Acamprosate calcium oral tablet, Mylan Institutional, 333 mg, unit-dose 50 count, NDC 51079-0241-06

Estimated Resupply Dates

- All presentations are currently available.

Updated

Updated May 26, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Created January 30, 2015 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.